Related Experiment Video
Updated: Mar 6, 2026
Imaging Analysis of Neuron to Glia Interaction in Microfluidic Culture Platform MCP-based Neuronal Axon and Glia Co-culture System
Published on: October 14, 2012
Dexmedetomidine Attenuates Lipopolysaccharide Induced MCP-1 Expression in Primary Astrocyte
Huan Liu1, Jacques R J Davis1, Zhi-Lin Wu1
1Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Abstract:
Background. Neuroinflammation which presents as a possible mechanism of delirium is associated with MCP-1, an important proinflammatory factor which is expressed on astrocytes. It is known that dexmedetomidine (DEX) possesses potent anti-inflammatory properties. This study aimed to investigate the potential effects of DEX on the production of MCP-1 in lipopolysaccharide-stimulated astrocytes. Materials and Methods. Astrocytes were treated with LPS (10 ng/ml, 50 ng/ml, 100 ng/ml, and 1000 ng/ml), DEX (500 ng/mL), LPS (100 ng/ml), and DEX (10, 100, and 500 ng/mL) for a duration of three hours; expression levels of MCP-1 were measured by real-time PCR. The double immunofluorescence staining protocol was utilized to determine the expression of α2-adrenoceptors (α2AR) and glial fibrillary acidic protein (GFAP) on astrocytes. Results. Expressions of MCP-1 mRNA in astrocytes were induced dose-dependently by LPS. Administration of DEX significantly inhibited the expression of MCP-1 mRNA (P < 0.001). Double immunofluorescence assay showed that α2AR colocalize with GFAP, which indicates the expression of α2-adrenoceptors in astrocytes. Conclusions. DEX is a potent suppressor of MCP-1 in astrocytes induced with lipopolysaccharide through α2A-adrenergic receptors, which potentially explains its beneficial effects in the treatment of delirium by attenuating neuroinflammation.
Insights
Dexmedetomidine (DEX) suppresses the inflammatory factor MCP-1 in astrocytes stimulated by lipopolysaccharide (LPS). This action, mediated by alpha2A-adrenergic receptors, suggests DEX may reduce neuroinflammation in conditions like delirium.
Area of Science:
- Neuroscience
- Pharmacology
- Immunology
Background:
- Neuroinflammation is implicated in delirium pathogenesis.
- Monocyte chemoattractant protein-1 (MCP-1) is a key pro-inflammatory factor expressed by astrocytes.
- Dexmedetomidine (DEX) exhibits significant anti-inflammatory properties.
Purpose of the Study:
- To investigate the effect of DEX on MCP-1 production in astrocytes stimulated by lipopolysaccharide (LPS).
- To explore the role of alpha2-adrenoceptors (α2AR) in DEX's anti-inflammatory action on astrocytes.
Main Methods:
- Astrocytes were treated with varying concentrations of LPS and DEX.
- MCP-1 mRNA expression was quantified using real-time PCR.
- Immunofluorescence staining identified the co-localization of α2AR and glial fibrillary acidic protein (GFAP) on astrocytes.
Main Results:
- LPS dose-dependently increased MCP-1 mRNA expression in astrocytes.
- DEX significantly inhibited LPS-induced MCP-1 mRNA expression (P < 0.001).
- α2AR were confirmed to be expressed on astrocytes, co-localizing with GFAP.
Conclusions:
- DEX effectively suppresses LPS-induced MCP-1 production in astrocytes.
- This inhibitory effect is mediated via α2A-adrenergic receptors.
- DEX's ability to attenuate neuroinflammation may contribute to its therapeutic benefits in delirium.
